PubMed · 10234664
177Lu-EDTMP: a potential therapeutic bone agent.
Abstract
Lutetium-177 (177Lu) has both beta particle emissions for a therapeutic effect and gamma emissions for imaging. This study was undertaken to synthesize and evaluate 177Lu-EDTMP (ethylenediaminetetramethylene phosphonic acid) as a therapeutic radiopharmaceutical for the palliation of pain from bone metastases. Chelation of 177Lu to EDTMP was obtained by heating for 30 min in boiling water at pH 8.8, resulting in a radiochemical yield of over 99%. The compound was stable for 20 days without any appreciable dissociation. Biodistribution studies in normal rats indicated selective bone accumulation, showing faster blood clearance, higher bone uptake and higher bone-to-soft tissue ratios than 99Tcm-MDP. In conclusion, 177Lu-EDTMP has favourable biological and physical characteristics for the palliative treatment of painful bone metastases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
A Ando, I Ando, N Tonami, S Kinuya, K Kazuma, A Kataiwa, M Nakagawa, N Fujita. 1998. 177Lu-EDTMP: a potential therapeutic bone agent.. https://pubmed.health/record/pubmed%3A10234664/177lu-edtmp-a-potential-therapeutic-bone-agent
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.